Physician profile
Lawrence Green
NPI 1386692333
$192,696.13
in general payments reported to CMS, 2019-2025
39 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $23K · 2021: $38K · 2022: $58K · 2023: $10K · 2024: $9,867 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,094 · Honoraria: $4,200 · Consulting Fee: $3,864 · Food and Beverage: $3,238 · Travel and Lodging: $2,417 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,094.00 |
| Honoraria | $4,200.00 |
| Consulting Fee | $3,864.32 |
| Food and Beverage | $3,237.53 |
| Travel and Lodging | $2,416.53 |
| Education | $152.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $45,384.13 | 2020-2024 | Zeposia |
| Biogen, INC. | $38,376.21 | 2019-2024 | Tysabri, Vumerity |
| Genentech USA, INC. | $24,552.75 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Teva Pharmaceuticals USA, INC. | $24,306.86 | 2019-2025 | Austedo Xr, Ajovy |
| Lundbeck LLC | $22,789.10 | 2020-2025 | Vyepti |
| Celgene Corporation | $16,766.86 | 2019-2025 | Zeposia |
| Emd Serono, INC. | $8,907.94 | 2019-2024 | Mavenclad |
| Genzyme Corporation | $6,596.88 | 2019-2022 | |
| US Oncology Corporate, INC. | $1,336.62 | 2023 | |
| Abbvie INC. | $564.59 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $555.74 | 2019-2022 | |
| Tg Therapeutics, INC. | $292.87 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $291.36 | 2019-2023 | |
| Axsome Therapeutics, INC. | $262.94 | 2025 | Symbravo |
| Lilly USA, LLC | $181.15 | 2019-2025 | Kisunla, Amyvid |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $178.70 | 2020-2022 | |
| Kyowa Kirin, INC. | $158.88 | 2020-2022 | |
| Ucb, INC. | $142.32 | 2019-2025 | Fintepla |
| Eisai INC. | $133.36 | 2021-2024 | |
| Allergan, INC. | $123.90 | 2020 | |
| Argenx US, INC. | $97.48 | 2022 | |
| Acorda Therapeutics, INC | $83.20 | 2019 | |
| Amgen INC. | $69.99 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $67.87 | 2021 | |
| C2n Diagnostics, LLC | $61.40 | 2025 | Precivityad2 |
| Adamas Pharmaceuticals, INC. | $60.40 | 2019-2020 | |
| Genentech, INC. | $50.00 | 2019-2023 | Ocrevus |
| Revance Therapeutics, INC. | $42.43 | 2025 | Daxxify |
| Boston Scientific Corporation | $41.64 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.75 | 2022 | |
| Amneal Pharmaceuticals LLC | $34.27 | 2022-2024 | Ongentys |
| Sandoz INC. | $33.39 | 2023 | |
| Aucta Pharmaceuticals, INC. | $23.55 | 2024 | Motpoly Xr |
| Vanda Pharmaceuticals INC. | $17.71 | 2024 | Ponvory |
| Astrazeneca Pharmaceuticals Lp | $17.50 | 2024 | |
| Banner Life Sciences, LLC | $15.20 | 2022 | |
| Merck Sharp & Dohme LLC | $15.15 | 2021 | |
| Aquestive Therapeutics, INC. | $12.81 | 2020 | |
| Abbott Laboratories | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.